<DOC>
	<DOC>NCT00391248</DOC>
	<brief_summary>To improve the clinical outcomes of patients with non-small cell lung cancer treated with radiation therapy.</brief_summary>
	<brief_title>Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation Therapy for Non-small Cell Lung Cancer (PEARL)</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Histologically confirmed nonsmall cell lung cancer (squamous cell, adenocarcinoma, poorly differentiated nonsmall cell carcinoma, or some combination of these); and Symptomatic patients (defined at discretion of investigator) for whom palliative thoracic radiation is planned (3000cGy/10 fractions); and At least 18 years of age. Previous erlotinib therapy; or Planned concurrent chemotherapy; or Expected survival of less than 3 months; or ECOG Performance Status of 3 or 4; or Multiple CNS metastasis or a single CNS lesion that has not demonstrated radiologic stability (screening CT/MRI or head not required); or Granulocyte count &lt;1,500/mm3, platelet count &lt;100,000/mm3, or haemoglobin &lt;9.0g/dl; or SGOT (AST) or SGPT (ALT) &gt; 2.5 times (x) upper limit of normal (ULN) in the absence of known liver metastases or &gt; 5 x ULN in case of known liver metastases; or Alkaline phosphatase (ALP) &gt; 2.5 x ULN; or Serum bilirubin &gt; 1.5 ULN; or Serum creatinine &gt; 1.5 ULN or creatinine clearance &lt; 60 ml/min; or Serum calcium beyond ULN; or Patients requiring systemic antifungal therapy, clarithromycin, phenytoin, or oral anticoagulation therapy (see Appendix VI for complete list of medications); or A history of interstitial lung disease; or Known sensitivity to erlotinib; or Pregnancy, lactation, or parturition within the previous 30 days; or Unwillingness or inability to complete the required assessments of the trial; or Mental incompetence, including psychiatric or addictive disorders which would preclude meaningful informed consent; or History of recurrent conjunctivitis or keratitis or other inflammatory changes of the surface of the eye. Geographically inaccessible for treatment or followup evaluations; or Involved in an ongoing therapeutic trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>palliative radiation</keyword>
	<keyword>tarceva</keyword>
	<keyword>palliative thoracic radiation therapy</keyword>
</DOC>